Ryley McPeters, MD
Interventional Cardiology · Nampa, IDNPI 1730543646
Payments from drug & device makers
What this record shows
This record is dominated by grants: $4,000 of the $5,969 with a category attached, or 67.0%. Medtronic accounts for 72.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $4,499 and has fallen 89.6% since, to $466 in 2025.
Across 38 payments — averaging $157.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Shockwave Medical, Inc$423
- E.r. Squibb & Sons, L.L.C.$225
- Abiomed$157
- Philips North America LLC$136
- Inari Medical, Inc.$109
- plus $615 from 16 others
What the payments were for
- Grants$4,00067%
- Food & beverage$1,80530%
- Education$1643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 3 | $4,303 |
| Shockwave Medical, Inc | 3 | $423 |
| E.r. Squibb & Sons, L.L.C. | 3 | $225 |
| Abiomed | 3 | $157 |
| Philips North America LLC | 1 | $136 |
| Inari Medical, Inc. | 1 | $109 |
| Amgen | 1 | $92 |
| Novo Nordisk | 3 | $85 |
| Angiodynamics, Inc. | 1 | $69 |
| Pfizer | 2 | $62 |
| AstraZeneca | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Johnson & Johnson | 2 | $31 |
| Convatec Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Novartis | 1 | $22 |
| Livanova USA, Inc. | 1 | $19 |
| Saranas, Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Merck | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,969 in reported general payments places this provider in the 70th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 23 | $116 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Nampa
- Andrew MichaelsNampa$7K
- George SamaanNampa$6K
- Rosie JasperNampa$4K
- Nicholas HodgmanNampa$3K
- Trey OxfordNampa$547
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.